Back to results
US 4,988,682 AGranted
Myo-inositol analogs and method for their use
AssigneeUniversity of Pittsburgh
InventorAlan P. Kozikowski
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for inhibiting the phosphatidylinositol cycle in a cell by contacting the cell with certain myo-inositol analogs. Such myo-inositol analogs can also be utilized to treat phosphatidylinositol cycle-dependent conditions. The present invention also provides novel myo-inositol analogs.
Claims16
A compound represented by the general formula II:
- ##STR17## wherein:
- R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 is each independently selected from the group consisting of OH, F, N.sub.3, NH.sub.2, SH, SeH, Cl Br, I and CN;
- with the proviso:
- (i) four or five of said R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are OH;
- (ii) if one of said R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 is N.sub.3, then one of said R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 is selected from the group consisting of F, NH.sub.2, SH, SeH, Cl, Br, I and CN;
- (iii) if one of said R.sup.1, R.sup.1 2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 is NH.sub.2, then one of said R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 is selected from the group consisting of F, N.sub.3, SH, SeH, Cl, Br, I and CN;
- and
- (iv) if said R.sup.4, R.sup.5 or R.sup.6 is F, Cl, Br or I then four of said R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are OH.
5 more elements
A pharmaceutical composition comprising a therapeutically effective amount for inhibiting the phosphatidylinositol cycle in a manual of a compound represented by the general formula III:
- ##STR18## wherein:
- R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, and R.sup.6 is each independently selected from the group consisting of OH, F, N.sub.3, NH.sub.2, SH, SeH, Cl, Br, I and CN;
- with the proviso:
- (i) four or five of said R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, and R.sup.6 are OH;
- (ii) if one of said R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 is N.sub.3, then one of said R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, and R.sup.6 is selected from the group consisting of F, NH.sub.2, SH, SeH, Cl, Br, I and CN;
- (iii) if one of said R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, and R.sup.6 is NH.sub.2, then one of said R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, and R.sup.6 is selected from the group consisting of F, N.sub.3, SH, SeH, Cl, Br, I and CN;
- and
- (iv) if said R.sup.4, R.sup.5, and R.sup.6 is F, Cl, Br, or I then four of said R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, and R.sup.6 are OH, and a pharmaceutically acceptable carrier.
5 more elements
Dependencies are inferred from the claim text.